{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:57:08Z","timestamp":1790193428152,"version":"4.1.0"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Anti-mitochondrial antibodies (AMA) and the M2 subtype are considered serological hallmarks in the diagnosis of primary biliary cholangitis (PBC). However, these autoantibodies may be undetectable in some patients. This meta-analysis aimed to evaluate the diagnostic accuracy of serum AMA and M2 for PBC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library for relevant studies. Pooled sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR\u2212), and diagnostic odds ratio (DOR) were calculated using a random-effects model. We also constructed hierarchical summary receiver operating characteristic curves and calculated the area under the curve values.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Our meta-analysis included 28 studies, of which 24 examined the diagnostic accuracy of AMA for PBC. Pooled sensitivity and specificity of AMA were 84% (95% confidence intervals [CI] 77\u201390%) and 98% (96\u201399%), respectively. Pooled LR+, LR\u2212, and DOR were 42.2 (22.1\u201380.5), 0.16 (0.11\u20130.24), and 262 (114\u2013601), respectively. Sixteen studies explored the diagnostic value of the M2 subtype, demonstrating pooled sensitivity and specificity of 89% (81\u201394%) and 96% (93\u201398%), respectively. Pooled LR+, LR\u2212, and DOR were 20.3 (8.0\u201351.1), 0.12 (0.05\u20130.26), and 169 (41\u2013706), respectively. The hierarchical summary receiver operating characteristic curves for both of serum AMA and M2 subtype lie closer to the upper left corner of the plot with area under the curve values of 0.98 (95% CI\u2005=\u20050.96\u20130.99) and 0.98 (95% CI\u2005=\u20050.96\u20130.99) respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This meta-analysis provides evidence affirming the utility of AMA and M2 as sensitive and specific serological hallmarks that can facilitate early screening and diagnosis of PBC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000036039","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T19:01:33Z","timestamp":1699642893000},"page":"e36039","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Diagnostic value of anti-mitochondrial antibody in patients with primary biliary cholangitis: A systemic review and meta-analysis"],"prefix":"10.1097","volume":"102","author":[{"given":"Qingling","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Wuxi Xinwu District Xinrui Hospital, Jiangsu Wuxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Wuxi Xinwu District Xinrui Hospital, Jiangsu Wuxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-3397","authenticated-orcid":false,"given":"Yufeng","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The First Affiliated Hospital of Soochow University, Jiangsu Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1164202","DOI":"10.3389\/fimmu.2023.1164202","article-title":"Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products.","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jhep.2015.07.038","article-title":"Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.","volume":"63","author":"Bosch","year":"2015","journal-title":"J Hepatol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"102328","DOI":"10.1016\/j.jaut.2019.102328","article-title":"The challenges of primary biliary cholangitis: what is new and what needs to be done.","volume":"105","author":"Terziroli Beretta-Piccoli","year":"2019","journal-title":"J Autoimmun"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1184252","DOI":"10.3389\/fimmu.2023.1184252","article-title":"Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0039-1688751","article-title":"The contribution of B cells in autoimmune liver diseases.","volume":"39","author":"Taylor","year":"2019","journal-title":"Semin Liver Dis"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"975115","DOI":"10.3389\/fimmu.2022.975115","article-title":"New insights on the role of human leukocyte antigen complex in primary biliary cholangitis.","volume":"13","author":"Mulinacci","year":"2022","journal-title":"Front Immunol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"100182","DOI":"10.1016\/j.jtauto.2022.100182","article-title":"Apoptotic biliary epithelial cells and gut dysbiosis in the induction of murine primary biliary cholangitis.","volume":"6","author":"Wang","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaut.2015.07.004","article-title":"The immunogenetics of primary biliary cirrhosis: a comprehensive review.","volume":"64","author":"Webb","year":"2015","journal-title":"J Autoimmun"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(65)91372-3","article-title":"Serological tests in diagnosis of primary biliary cirrhosis.","volume":"1","author":"Walker","year":"1965","journal-title":"Lancet"},{"key":"R10-20250504","first-page":"237","article-title":"Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications.","volume":"1","author":"Doniach","year":"1966","journal-title":"Clin Exp Immunol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.510250507","article-title":"Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis.","volume":"25","author":"Invernizzi","year":"1997","journal-title":"Hepatology"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hep.510300145","article-title":"In situ nucleic acid detection of PDC-E2, BCOADC-E2, OGDC-E2, PDC-E1alpha, BCOADC-E1alpha, OGDC-E1, and the E3 binding protein (protein X) in primary biliary cirrhosis.","volume":"30","author":"Harada","year":"1999","journal-title":"Hepatology"},{"key":"R13-20250504","first-page":"69","article-title":"The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients.","volume":"4","author":"Ergenc","year":"2023","journal-title":"Hepatol Forum"},{"key":"R14-20250504","first-page":"2052","article-title":"Screening of anti-mitochondrial antibody subtype M2 in residents at least 18 years of age in an urban district of Shanghai, China.","volume":"20","author":"Chen","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"117219","DOI":"10.1016\/j.cca.2023.117219","article-title":"Presence of anti-gp210 or anti-sp100 antibodies in AMA-positive patients may help support a diagnosis of primary biliary cholangitis.","volume":"540","author":"Jaskowski","year":"2023","journal-title":"Clinica Chimica Acta"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0168-8278(98)80233-X","article-title":"The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis.","volume":"28","author":"Luettig","year":"1998","journal-title":"J Hepatol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2174\/1574887117666220617095856","article-title":"Clinical patterns of primary biliary cholangitis: comparison between two European case series.","volume":"17","author":"Abenavoli","year":"2022","journal-title":"Rev Recent Clin Trials"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.medcli.2017.12.021","article-title":"Primary biliary cholangitis.","volume":"151","author":"Par\u00e9s","year":"2018","journal-title":"Med Clin"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/liv.14466","article-title":"Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis.","volume":"40","author":"Bossen","year":"2020","journal-title":"Liver Int"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/gut.13.11.926","article-title":"Alkaline phosphatase.","volume":"13","author":"Warnes","year":"1972","journal-title":"Gut"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/hepr.12809","article-title":"Positive antimitochondrial antibody but normal serum alkaline phosphatase levels: could it be primary biliary cholangitis?","volume":"47","author":"Berdichevski","year":"2017","journal-title":"Hepatol Res"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/cgh.2003.50014","article-title":"When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?","volume":"1","author":"Zein","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.cgh.2020.08.006","article-title":"Measurement of gamma glutamyl transferase to determine risk of liver transplantation or death in patients with primary biliary cholangitis.","volume":"19","author":"Gerussi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0016-5085(19)33896-X","article-title":"Paradoxical elevation of serum cholesterol by clofibrate in patients with primary biliary cirrhosis.","volume":"57","author":"Schaffner","year":"1969","journal-title":"Gastroenterology"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gut.20.2.137","article-title":"Serum bilirubin: a prognostic factor in primary biliary cirrhosis.","volume":"20","author":"Shapiro","year":"1979","journal-title":"Gut"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"The diagnosis and management of patients with primary biliary cholangitis.","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e0179","DOI":"10.1097\/HC9.0000000000000179","article-title":"Primary biliary cholangitis: epidemiology, prognosis, and treatment.","volume":"7","author":"Trivella","year":"2023","journal-title":"Hepatol Commun"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/liv.15386","article-title":"Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid.","volume":"42","author":"De Vincentis","year":"2022","journal-title":"Liver Int"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/diseases8020020","article-title":"Primary biliary cholangitis and bile acid Farnesoid X receptor agonists.","volume":"8","author":"Abenavoli","year":"2020","journal-title":"Diseases"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the study of liver diseases.","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement.","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1515\/cclm-2013-0926","article-title":"The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis.","volume":"52","author":"Hu","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.3899\/jrheum.090340","article-title":"Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients.","volume":"36","author":"Assassi","year":"2009","journal-title":"J Rheumatol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.510230512","article-title":"Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis.","volume":"23","author":"Bandin","year":"1996","journal-title":"Hepatology"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.patbio.2007.05.001","article-title":"Detection of M2 antimitochondrial antibodies by dot blot assay is more specific than by enzyme linked immunosorbent assay.","volume":"56","author":"Bargou","year":"2008","journal-title":"Pathol Biol (Paris)"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3899\/jrheum.110167","article-title":"Primary biliary cirrhosis-related autoantibodies in a large cohort of Italian patients with systemic sclerosis.","volume":"38","author":"Cavazzana","year":"2011","journal-title":"J Rheumatol"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2016.10.003","article-title":"Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis.","volume":"77","author":"Chung","year":"2017","journal-title":"J Autoimmun"},{"key":"R41-20250504","first-page":"640","article-title":"Detection of anti-mitochondrial antibodies by ELISA and Western-blot techniques and identification by one and two-dimensional gel electrophoresis of M2 target antigens.","volume":"70","author":"Dighiero","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s10875-007-9092-0","article-title":"Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis.","volume":"27","author":"Gabeta","year":"2007","journal-title":"J Clin Immunol"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.3748\/wjg.v27.i29.4890","article-title":"Poor performance of anti-mitochondrial antibodies for the diagnosis of primary biliary cholangitis in female Colombian patients: a single-center study.","volume":"27","author":"Guatibonza-Garc\u00eda","year":"2021","journal-title":"World J Gastroenterol"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cca.2016.11.021","article-title":"Clinical relevance of combined anti-mitochondrial M2 detection assays for primary biliary cirrhosis.","volume":"464","author":"Han","year":"2017","journal-title":"Clin Chim Acta"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1007\/s10620-011-1756-1","article-title":"Prevalence of autoimmune liver disease related autoantibodies in Chinese patients with primary biliary cirrhosis.","volume":"56","author":"Hu","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1386-6346(01)00075-4","article-title":"Development of a new enzyme-linked immunosorbent assay for the detection of anti-M2 in primary biliary cirrhosis.","volume":"21","author":"Jong-Hon","year":"2001","journal-title":"Hepatol Res"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1177\/31.10.6350436","article-title":"Antibodies to hepatocyte membrane antigens in chronic liver disease: detection by immunofluorescence after Bouin\u2019s fixation.","volume":"31","author":"Lee","year":"1983","journal-title":"J Histochem Cytochem"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1471-230X-10-100","article-title":"Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China.","volume":"10","author":"Liu","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jaut.2010.09.005","article-title":"PBC screen: an IgG\/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis.","volume":"35","author":"Liu","year":"2010","journal-title":"J Autoimmun"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2249.2004.02332.x","article-title":"\u201cTrue\u201d antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?","volume":"135","author":"Muratori","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0022-1759(83)90337-X","article-title":"Detection of mitochondrial antibodies directed against the primary biliary cirrhosis (M2) antigen by an enzyme-linked immunosorbent assay (ELISA).","volume":"60","author":"Nagai","year":"1983","journal-title":"J Immunol Methods"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.21583","article-title":"A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis.","volume":"45","author":"Oertelt","year":"2007","journal-title":"Hepatology"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1111\/j.1572-0241.2004.40416.x","article-title":"Serum immunological profile in patients with chronic autoimmune cholestasis.","volume":"99","author":"Romero-Gomez","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1386-6346(03)00167-0","article-title":"Epidemiology of primary biliary cirrhosis among women with elevated gamma-glutamyl transpeptidase levels in Okinawa, Japan.","volume":"26","author":"Sakugawa","year":"2003","journal-title":"Hepatol Res"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"389","DOI":"10.21037\/atm.2019.07.100","article-title":"The expression and clinical significance of serum IL-17 in patients with primary biliary cirrhosis.","volume":"7","author":"Sun","year":"2019","journal-title":"Ann Transl Med"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cca.2014.08.024","article-title":"Autoantibody profiling of patients with primary biliary cirrhosis using a multiplexed line-blot assay.","volume":"438","author":"Villalta","year":"2015","journal-title":"Clin Chim Acta"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10620-014-3372-3","article-title":"Increased numbers of circulating ICOS (+) follicular helper T and CD38 (+) plasma cells in patients with newly diagnosed primary biliary cirrhosis.","volume":"60","author":"Wang","year":"2015","journal-title":"Dig Dis Sci"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"7579","DOI":"10.3748\/wjg.v22.i33.7579","article-title":"Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis.","volume":"22","author":"Yang","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clinbiochem.2011.08.1146","article-title":"Clinical significance of conventional serum autoantibodies for various liver diseases in a Chinese population.","volume":"45","author":"Yang","year":"2012","journal-title":"Clin Biochem"},{"key":"R60-20250504","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jrsm.1647","article-title":"Estimation of heterogeneity variance based on a generalized Q statistic in meta-analysis of log-odds-ratio.","volume":"14","author":"Kulinskaya","year":"2023","journal-title":"Res Synth Methods"},{"key":"R61-20250504","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12016-021-08904-y","article-title":"Antimitochondrial antibodies: from bench to bedside.","volume":"63","author":"Colapietro","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"R62-20250504","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.23783","article-title":"Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis.","volume":"52","author":"Lleo","year":"2010","journal-title":"Hepatology"},{"key":"R63-20250504","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3748\/wjg.14.3328","article-title":"Etiopathogenesis of primary biliary cirrhosis.","volume":"14","author":"Lleo","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R64-20250504","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/hep4.2067","article-title":"The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti-mitochondrial antibodies but without baseline PBC.","volume":"6","author":"Duan","year":"2022","journal-title":"Hepatol Commun"},{"key":"R65-20250504","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0002-9343(73)90058-2","article-title":"Hepatobiliary diseases associated with serum antimitochondrial antibody (AMA).","volume":"54","author":"Kaplowitz","year":"1973","journal-title":"Am J Med"},{"key":"R66-20250504","doi-asserted-by":"crossref","first-page":"102706","DOI":"10.1016\/j.jaut.2021.102706","article-title":"Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: a novel clinical entity?","volume":"123","author":"Ghielmetti","year":"2021","journal-title":"J Autoimmun"},{"key":"R67-20250504","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/gut.35.2.260","article-title":"Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis.","volume":"35","author":"Michieletti","year":"1994","journal-title":"Gut"},{"key":"R68-20250504","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/liv.15079","article-title":"Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis.","volume":"42","author":"John","year":"2022","journal-title":"Liver Int"},{"key":"R69-20250504","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines.","volume":"67","author":"Gideon","year":"2018","journal-title":"Gut"},{"key":"R70-20250504","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.livres.2018.03.004","article-title":"Primary biliary cholangitis: diagnosis and treatment.","volume":"2","author":"Chew","year":"2018","journal-title":"Liver Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:30:18Z","timestamp":1746325818000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":70,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036039","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]}}}